{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0.1","upperLimit":"0.7","value":"0.2"},{"comment":"Values were below the level of quantification.","groupId":"OG001","lowerLimit":"NA","upperLimit":"NA","value":"NA"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"17"},{"groupId":"OG001","value":"10"}],"units":"Participants"}],"description":"Certolizumab pegol plasma concentration was measured at the Follow-Up Visit, in µg/mL.\n\nFollow-Up Visit was defined as 8 weeks after Week 52 or Withdrawal (WD) visit for subjects not participating in the Safety Follow-Up Extension (SFE) Period.","dispersionType":"95% Confidence Interval","groups":[{"description":"Certolizumab pegol (CZP) 400 mg subcutaneous (sc) on Weeks 0, 2 and 4, followed by 200 mg CZP sc every 2 weeks (Q2W) from Week 6 onwards. Subjects formed the SS.","id":"OG000","title":"CZP 200 mg Q2W (SS)"},{"description":"Subset of subjects from the Placebo group, who discontinued the CZP double-blind treatment and entered the open-label CZP treatment. The subjects were included in the SS for safety analysis.","id":"OG001","title":"Placebo->OL CZP (SS)"}],"paramType":"GEOMETRIC_MEAN","populationDescription":"The SS consisted of all subjects who received at least 1 dose of study treatment. Only participants included, who had a SFU Visit at 8 weeks after Week 52/WD visit for those not participating in the SFE period.","reportingStatus":"POSTED","timeFrame":"Follow-up Visit (up to Week 60)","title":"Certolizumab Pegol Plasma Concentration at Follow-Up (FU) Visit","type":"PRIMARY","unitOfMeasure":"µg/mL"}